NXEN / Nexien BioPharma, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA, INC.

Amendment and Third Extension of Note Purchase Agreement between the Company and Richard Greenberg dated November 9, 2024

Exhibit 10.17 AMENDMENT AND THIRD EXTENSION OF NOTE PURCHASE AGREEMENT THIS AMENDMENT AND THIRD EXTENSION OF NOTE PURCHASE AGREEMENT (this “Amendment”), dated as of June 30, 2024, (the “Execution Date”), is entered into by and between NEXIEN BIOPHARMA, INC., a Delaware corporation (the “Company”), and Richard Greenberg (the “Buyer”). WHEREAS, the Company and the Buyer entered into a Note Purchase

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA, I

Convertible Promissory Note dated November 4, 2024 issued to Alain Bankier

Exhibit 10.16 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-55320 FORM 12b-25 CUSIP NUMBER 65343D 100 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ T

Note Purchase Agreement dated October 3, 2024 between the Company and Quick Capital, LLC (9)

Exhibit 10.14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-55320 NEXIEN BIOPHARMA, INC. (Exact name of registrant as specified in i

Convertible Promissory Note dated October 3, 2024 issued to Quick Capital, LLC (9)

Exhibit 10.15

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-55320 FORM 12b-25 CUSIP NUMBER 65343D 100 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi

Amendment and Second Extension of Note Purchase Agreement between the Company and Richard Greenberg dated February 29, 2024 (8)

Exhibit 10.13 AMENDMENT AND SECOND EXTENSION OF NOTE PURCHASE AGREEMENT THIS AMENDMENT AND SECOND EXTENSION OF NOTE PURCHASE AGREEMENT (this “Amendment”), dated as of February 29, 2024, (the “Execution Date”), is entered into by and between NEXIEN BIOPHARMA, INC., a Delaware corporation (the “Company”), and Richard Greenberg (the “Buyer”). WHEREAS, the Company and the Buyer entered into a Note Pur

Convertible Promissory Note dated February 14, 2024 issued to Quick Capital, LLC (8)

Exhibit 10.12

Note Purchase Agreement dated February 14, 2024 between the Company and Quick Capital, LLC (8)

Exhibit 10.11

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA, INC.

Note Purchase Agreement dated February 14, 2024 between the Company and Quick Capital, LLC

Exhibit 10.11 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of February 14, 2024, (the “Execution Date”), is entered into by and between NEXIEN BIOPHARMA, INC., a Delaware corporation (the “Company”), and QUICK CAPITAL, LLC, a Wyoming limited liability company (the “Buyer”). Each capitalized term used herein shall have the meaning ascribed thereto in Section 10

Convertible Promissory Note dated February 14, 2024 issued to Quick Capital, LLC

Exhibit 10.12 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-55320 FORM 12b-25 CUSIP NUMBER 65343D 100 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA,

Amendment and Extension of Note Purchase Agreement dated May 8, 2023 (7)

Exhibit 10.10 AMENDMENT AND EXTENSION OF NOTE PURCHASE AGREEMENT THIS AMENDMENT AND EXTENSION OF NOTE PURCHASE AGREEMENT (this “Amendment”), dated as of May 8, 2023, (the “Execution Date”), is entered into by and between NEXIEN BIOPHARMA, INC., a Delaware corporation (the “Company”), and QUICK CAPITAL, LLC, a Wyoming limited liability company (the “Buyer”). WHEREAS, the Company and the Buyer enter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-55320 NEXIEN BIOPHARMA, INC. (Exact name of registrant as specified in i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-55320 NEXIEN BIOPHARMA, INC. (Exact name of registrant as specified in i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA, I

Common Stock Purchase Warrant dated January 18, 2022 issued to Quick Capital, LLC (6)

Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 18, 2022 Nexien BioPharma, Inc. (Exact name of registrant as specified in its charter) Commission File No.: 0-55320 Delaware 26-2049376 (State or other jurisdiction of incorpo

Convertible Promissory Note dated January 18, 2022 issued to Quick Capital, LLC (6)

Exhibit 10.2 NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR

Note Purchase Agreement dated January 18, 2022 between and Company and Quick Capital, LLC (6)

Exhibit 10.1 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this ?Agreement?), dated as of January 18, 2022, (the ?Execution Date?), is entered into by and between NEXIEN BIOPHARMA, INC., a Delaware corporation (the ?Company?), and QUICK CAPITAL, LLC, a Wyoming limited liability company (the ?Buyer?). Each capitalized term used herein shall have the meaning ascribed thereto in Section 10 be

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-55320 NEXIEN BIOPHARMA, INC. (Exact name of registrant as specified in i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [X] Form 10-K [??] Form 20-F [??] Form 11-K [??] Form 10-Q [??] Form N-SAR [??] Form N-CSR For Period Ended: June 30, 2021 [??] Transition Report on Form 10-K [??] Transition Report on Form 20-F [??] Transition Report on Form 11-K [??] Transition Report on Form 10-Q [??] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA,

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARM

Convertible Promissory Note and Warrants dated November 24, 2020 to Richard Greenberg (5)

Exhibit 10.7 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHAR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended June 30, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-55320 NEXIEN BIOPHARMA, INC. (Exact name of registrant as specified

Demand Convertible Promissory Note dated June 11, 2020 to Richard Greenberg (4)

Exhibit 10.6 DEMAND CONVERTIBLE PROMISSORY NOTE $25,000.00 Denver, Colorado June 11, 2020 FOR VALUE RECEIVED, the undersigned, Nexien BioPharma, Inc., a Delaware corporation (the “Maker”), promises to pay to the order of Richard Greenberg, an individual residing in Colorado (“Payee”), on demand, the principal amount owed to Payee at the time of the demand, up to but not more than Twenty-Five Thous

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 14, 2020 Nexien BioPharma, Inc. (Exact name of registrant as specified in its charter) Commission File No.: 0-55320 Delaware 26-2049376 (State or other jurisdiction of incorporat

Nexien BioPharma, Inc. has been Issued a U.S. Patent for the Methods and Compositions for Treating Non-Dystrophic Myotonia and Myotonic Dystrophies Types 1 and 2 The patent relates to the administration of a specific composition comprised of cannabin

Exhibit 99.1 Nexien BioPharma, Inc. has been Issued a U.S. Patent for the Methods and Compositions for Treating Non-Dystrophic Myotonia and Myotonic Dystrophies Types 1 and 2 The patent relates to the administration of a specific composition comprised of cannabinoids to a patient Denver, Colorado, July 14, 2020 - The United States Patent and Trademark Office (USPTO) has issued a patent to Nexien B

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 31, 2020 Nexien BioPharma, Inc. (Exact name of registrant as specified in its charter) Commission File No.: 0-55320 Delaware 26-2049376 (State or other jurisdiction of incorpora

NTVA / Intiva BioPharma Inc. 10-Q - Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARM

NTVA / Intiva BioPharma Inc. 10-Q - Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHAR

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 21, 2019 Nexien BioPharma, Inc. (Exact name of registrant as specified in its charter) Commission File No.: 0-55320 Delaware 26-2049376 (State or other jurisdiction of incorpo

NTVA / Intiva BioPharma Inc. 10-K - Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 0-55320 (Commission File Number) NEXIEN BIOPHARMA, INC. (Exact name of registrant

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 18, 2019 Nexien BioPharma, Inc. (Exact name of registrant as specified in its charter) Commission File No.: 0-55320 Delaware 26-2049376 (State or other jurisdiction of incorporat

Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity - two common nerve agents

Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity - two common nerve agents Denver, CO, July 18, 2019 – Nexien BioPharma, Inc.

NTVA / Intiva BioPharma Inc. 10-Q Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-55320 (Commission file number) NEXIEN BIOPHARMA,

NTVA / Intiva BioPharma Inc. / Intiva Usa Inc - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to SCHEDULE 13D Under the Securities Exchange Act of 1934 Nexien BioPharma, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 46116E 103 (CUSIP Number) Evan Wasoff 4340 E. Kentucky Avenue, Suite 206 Glendale, Colorado 80246 (Name, Address and Telephone Number of Pers

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 1, 2019 Nexien BioPharma, Inc. (Exact name of registrant as specified in its charter) Commission File No.: 0-55320 Delaware 26-2049376 (State or other jurisdiction of incorporat

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 29, 2019 Nexien BioPharma, Inc. (Exact name of registrant as specified in its charter) Commission File No.: 0-55320 Delaware 26-2049376 (State or other jurisdiction of incorpora

Investor presentation

EX-99.1 2 ex99-1.htm

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 8, 2019 Nexien BioPharma, Inc. (Exact name of registrant as specified in its charter) Commission File No.: 0-55320 Delaware 26-2049376 (State or other jurisdiction of incorporat

NTVA / Intiva BioPharma Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Definitive Information Statement NEXIEN BIOPHA

Nexien BioPharma Announces Acceptance of Patent Application No. 238946 by Israeli Patent Office — Patent covers use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity —

Nexien BioPharma Announces Acceptance of Patent Application No. 238946 by Israeli Patent Office — Patent covers use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity — Denver, CO, March 5, 2019 – Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of n

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 5, 2019 Nexien BioPharma, Inc. (Exact name of registrant as specified in its charter) Commission File No.: 0-55320 Delaware 26-2049376 (State or other jurisdiction of incorporat

Nexien BioPharma to File Pre-IND Meeting Request with the FDA — Encouraging clinical observations and patient questionnaire results indicate that specific cannabinoid formulations are supportive in the treatment of patients suffering from myotonic dy

EX-99.1 2 ex99-1.htm Nexien BioPharma to File Pre-IND Meeting Request with the FDA — Encouraging clinical observations and patient questionnaire results indicate that specific cannabinoid formulations are supportive in the treatment of patients suffering from myotonic dystrophy — Denver, CO, February 26, 2019 – Nexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation bio

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 26, 2019 Nexien BioPharma, Inc. (Exact name of registrant as specified in its charter) Commission File No.: 0-55320 Delaware 26-2049376 (State or other jurisdiction of incorp

NTVA / Intiva BioPharma Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 0-55320 (Commission file number) NEXIEN BIOPHARMA,

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 5, 2018 Nexien BioPharma, Inc. (Exact name of registrant as specified in its charter) Commission File No.: 0-55320 Delaware 26-2049376 (State or other jurisdiction of incorpo

Letter to Stockholders dated December 5, 2018

4340 E Kentucky Ave Suite 206 Glendale, CO 80246 www.nexienbiopharma.com OTC QB: NXEN December 5, 2018 Dear Nexien BioPharma shareholders and friends, Since May 9, 2018, when Alain Bankier sent out the last shareholder letter, we have been very busy at Nexien BioPharma (“Nexien” or the “Company”) building the foundation for a bio-pharmaceutical company. This joint letter from Alain, the former CEO

NTVA / Intiva BioPharma Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 000-28867 (Commission file number) NEXIEN BIOPHAR

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 5, 2018 Nexien BioPharma, Inc. (Exact name of registrant as specified in its charter) Commission File No.: 0-55320 Delaware 26-2049376 (State or other jurisdiction of incorpo

Nexien BioPharma Advances in Clinical Use of a Cannabinoid-Based Formulation for the Treatment of Myotonic Dystrophies and Myotonia

Nexien BioPharma Advances in Clinical Use of a Cannabinoid-Based Formulation for the Treatment of Myotonic Dystrophies and Myotonia Denver, Colorado, November 5, 2018 Nexien BioPharma Inc.

Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 26, 2018 Nexien BioPharma, Inc. (Exact name of registrant as specified in its charter) Commission File No.: 0-55320 Delaware 26-2049376 (State or other jurisdiction of incorpo

Nexien BioPharma Acquires Princeton-Based CRx Bio and Announces Additions to Senior Management CRx BIO is a researcher and developer of advanced cannabinoid-based therapeutic formulations

Nexien BioPharma Acquires Princeton-Based CRx Bio and Announces Additions to Senior Management CRx BIO is a researcher and developer of advanced cannabinoid-based therapeutic formulations Denver, Colorado, October 30, 2018 Nexien BioPharma, Inc.

Limited Liability Company Interest Purchase Agreement by and among the Members of CRX Bio Holdings LLC and Nexien BioPharma, Inc. dated October 26, 2018 (1)

LIMITED LIABILITY COMPANY INTEREST PURCHASE AGREEMENT BY AND AMONG THE MEMBERS OF CRX BIO HOLDINGS LLC AND NEXIEN BIOPHARMA, INC.

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 19, 2018 Nexien BioPharma, Inc. (Exact name of registrant as specified in its charter) Commission File No.: 0-55320 Delaware 26-2049376 (State or other jurisdiction of incorpo

NEXIEN BioPharma Inc.

NEXIEN BioPharma Inc. Announces Symbol Change to NXEN DENVER, CO / ACCESSWIRE / October 19, 2018 / Nexien BioPharma Inc. (OTCQB: NXEN) (formerly Intiva BioPharma Inc.) (the “Company”) today announced that effective as of October 19, 2018, the Company will trade on the OTCQB under the new stock symbol NXEN. Commenting on the symbol change, Alain Bankier, the Interim CEO of Nexien stated, “The new s

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 25, 2018 Nexien BioPharma, Inc. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Empl

INTIVA BioPharma Inc. Announces Name Change to Nexien BioPharma Inc.

INTIVA BioPharma Inc. Announces Name Change to Nexien BioPharma Inc. DENVER, CO / ACCESSWIRE / October 1, 2018 / Intiva BioPharma Inc. (OTCQB: NTVA) (the “Company”) announces that the Company has changed its corporate name to Nexien BioPharma Inc. (“Nexien”). The new corporate name, Nexien BioPharma, was inspired by the Company’s mission of becoming a global leader in the further evolution of cann

First Amendment to Exclusive License Agreement between the Company and Accu-Break Pharmaceuticals, Inc. dated September 18, 2018 (4)

FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT THIS FIRST AMENDMENT is made and entered into this 18th day of September, 2018 (the “Effective Date) between Accu-Break Pharmaceuticals, Inc.

Form of Class D Warrant (5)

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEME

Certificate of Amendment to Certificate of Incorporation (4)

Form of Class E Warrant (5)

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEME

NTVA / Intiva BioPharma Inc. 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 0-55320 (Commission File Number) NEXIEN BIOPHARMA, INC. (Exact name of registrant

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 12, 2018 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Emplo

INTIVA BioPharma (OTCQB-NTVA) Files a Listing Application with the Canadian Securities Exchange (CSE) The CSE listing, when approved, will increase Intiva BioPharma’s visibilty in the international financial community and help attract interest from g

INTIVA BioPharma (OTCQB-NTVA) Files a Listing Application with the Canadian Securities Exchange (CSE) The CSE listing, when approved, will increase Intiva BioPharma’s visibilty in the international financial community and help attract interest from global investors DENVER, CO / ACCESSWIRE / August 22, 2018 / INTIVA BioPharma Inc.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 22, 2018 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 10, 2018 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 27, 2018 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer I

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 19, 2018 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer I

INTIVA BioPharma Inc (NTVA) begins trading on the OTCQB Venture Market

INTIVA BioPharma Inc (NTVA) begins trading on the OTCQB Venture Market Denver, Colorado, July 19, 2018 - INTIVA BioPharma Inc.

INTIVA BioPharma Retains Dr. Benedikt Schoser as an Advisor Munich-based Dr. Schoser is a world-renowned expert on the molecular mechanisms of muscle loss and weakness, and myotonic dystrophy

INTIVA BioPharma Retains Dr. Benedikt Schoser as an Advisor Munich-based Dr. Schoser is a world-renowned expert on the molecular mechanisms of muscle loss and weakness, and myotonic dystrophy Denver, Colorado, July 12, 2018 - INTIVA BioPharma Inc. (“INTIVA” or the “Company”) (OTC: NTVA) today announced that Germany-based, Dr. Benedikt Schoser has been retained as an advisor to the Company. Dr. Sch

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 12, 2018 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer I

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 28, 2018 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer I

INTIVA BioPharma Files a U.S. Patent Application for the Use of Cannabinoids for Treating Myotonia, Myotonic Dystrophy and Other Related Dystrophies

INTIVA BioPharma Files a U.S. Patent Application for the Use of Cannabinoids for Treating Myotonia, Myotonic Dystrophy and Other Related Dystrophies Denver, Colorado, June 28, 2018 - INTIVA BioPharma Inc. (“INTIVA” or the “Company”) (OTC: NTVA) announced that it has filed a utility patent application with the United States Patent Office relating to the use of cannabinoids to treat myotonia, myoton

NTVA / Intiva BioPharma Inc. CORRESP

June 25, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, N.

NTVA / Intiva BioPharma Inc. S-1/A

As filed with the Securities and Exchange Commission on June 19 , 2018. Registration No. 333- 225477 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Intiva BioPharma Inc. (Exact name of registrant as specified in its charter) Delaware 8731 26-2049376 (State or other jurisdiction of incorpora

NTVA / Intiva BioPharma Inc. CORRESP

Intiva BioPharma Inc. 4340 East Kentucky Avenue Suite 206 Glendale, CO 80246 June 19, 2018 United States Securities and Exchange Commission Washington, DC 20549 Attn: Christine Westbrook, Staff Attorney Re: Intiva BioPharma Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed June 11, 2018 File No. 333-225477 Ladies and Gentlemen: This letter is in response to the staff’s comment lette

NTVA / Intiva BioPharma Inc. S-1/A

As filed with the Securities and Exchange Commission on June 11 , 2018. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Intiva BioPharma Inc. (Exact name of registrant as specified in its charter) Delaware 8731 26-2049376 (State or other jurisdiction of incorporation or

Subsidiaries of the Registrant

Exhibit 21.1 LIST OF SUBSIDIARIES The registrant has the following subsidiaries: Intiva BioPharma Inc., a Colorado corporation (“BioPharma”). It does not do business under any other name. BioPharma has two subsidiaries: ● Intiva Kotzker Pharmaceuticals Inc., a Colorado corporation ● Intiva Sharir Inc., a Colorado corporation Neither of these subsidiaries does business under any other names.

NTVA / Intiva BioPharma Inc. S-1

As filed with the Securities and Exchange Commission on June 7, 2018. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Intiva BioPharma Inc. (Exact name of registrant as specified in its charter) Delaware 8731 26-2049376 (State or other jurisdiction of incorporation or organization) (Prima

Other Events

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 4, 2018 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (

NTVA / Intiva BioPharma Inc. DRS/A

As filed with the Securities and Exchange Commission on , 2018. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Intiva BioPharma Inc. (Exact name of registrant as specified in its charter) Delaware 8731 26-2049376 (State or other jurisdiction of incorporation or organization) (Primary Sta

NTVA / Intiva BioPharma Inc. DRSLTR

Intiva BioPharma Inc. 4340 East Kentucky Avenue Suite 206 Glendale, CO 80246 May 16, 2018 United States Securities and Exchange Commission Washington, DC 20549 Attn: Christine Westbrook, Staff Attorney Re: Intiva BioPharma Inc. Amendment No. 1 to Draft Registration Statement (DRS) on Form S-1 Submitted April 4, 2018 CIK No. 0001625288 Ladies and Gentlemen: This letter is in response to the staff’s

Licensing Agreement between the Company and Kotzker Consulting LLC (3)

EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), effective as of this 29th day of March, 2017, between KOTZKER CONSULTING LLC, a Delaware limited liability company having a business address of 20 Highview Ln, Yardley, PA 19067 (the “LICENSOR”) and INTIVA KOTZKER PHARMACEUTICALS INC.

Certificate of Amendment to Certificate of Incorporation

Exclusive License Agreement between the Company and Accu-Break Pharmaceuticals, Inc.

EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), effective as of this 28th day of February, 2018, between ACCU-BREAK PHARMACEUTICALS, INC.

2018 Equity Incentive Plan

INTIVA BIOPHARMA INC. 2018 EQUITY INCENTIVE PLAN Table of Contents 1. PURPOSE 1 2. SHARES SUBJECT TO THE PLAN 1 2.1. Number of Shares Available 1 2.2. Lapsed, Returned Awards 1 2.3. Minimum Share Reserve 1 2.4. Automatic Share Reserve Increase 1 2.5. Limitations 2 2.6. Adjustment of Shares 2 3. ELIGIBILITY 2 4. ADMINISTRATION 2 4.1. Committee Composition; Authority 2 4.2. Committee Interpretation

2017 Stock Incentive Plan

INTIVA BIOPHARMA INC. 2017 STOCK INCENTIVE PLAN Section 1. Purpose. The purpose of this 2017 Stock Incentive Plan (the “Plan”) is to promote the interests of Intiva BioPharma Inc., a Colorado corporation (the “Company”), and the interests of the Company’s shareholders by attracting and retaining Employees, Non-Employee Directors and Consultants, and giving such persons the opportunity to acquire s

NTVA / Intiva BioPharma Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 Commission file number: 0-55320 Intiva BioPharma Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identific

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 9, 2018 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Ide

Letter to stockholders dated May 9, 2018

EX-20.1 2 ex20-1.htm May 9, 2018 Dear Shareholders and friends of IntivaBiopharma, We are pleased to provide you with an update regarding Intiva BioPharma Inc.’s (“Intiva”) recent developments, current activities and most importantly, some of our plans for the future. In March I was appointed Interim Chief Executive Officer of Intiva, upon Jeffrey Friedland’s resignation as an officer and director

Other Events

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 22, 2018 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation)

NTVA / Intiva BioPharma Inc. DRS/A

As filed with the Securities and Exchange Commission on , 2018. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Intiva BioPharma Inc. (Exact name of registrant as specified in its charter) Delaware 8731 26-2049376 (State or other jurisdiction of incorporation or organization) (Primary Sta

EX-3.4

INTIVA BIOPHARMA INC. 2018 EQUITY INCENTIVE PLAN Table of Contents

INTIVA BIOPHARMA INC. 2018 EQUITY INCENTIVE PLAN Table of Contents 1. PURPOSE 1 2. SHARES SUBJECT TO THE PLAN 1 2.1. Number of Shares Available 1 2.2. Lapsed, Returned Awards 1 2.3. Minimum Share Reserve 1 2.4. Automatic Share Reserve Increase 1 2.5. Limitations 2 2.6. Adjustment of Shares 2 3. ELIGIBILITY 2 4. ADMINISTRATION 2 4.1. Committee Composition; Authority 2 4.2. Committee Interpretation

LIST OF SUBSIDIARIES

Exhibit 21.1 LIST OF SUBSIDIARIES The registrant has the following subsidiaries: Intiva BioPharma Inc., a Colorado corporation (“BioPharma”). It does not do business under any other name. BioPharma has two subsidiaries: ● Intiva Kotzker Pharmaceuticals Inc., a Colorado corporation ● Intiva Sharir Inc., a Colorado corporation Neither of these subsidiaries does business under any other names.

EXCLUSIVE LICENSE AGREEMENT

EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), effective as of this 29th day of March, 2017, between KOTZKER CONSULTING LLC, a Delaware limited liability company having a business address of 20 Highview Ln, Yardley, PA 19067 (the “LICENSOR”) and INTIVA KOTZKER PHARMACEUTICALS INC.

NTVA / Intiva BioPharma Inc. DRSLTR

Intiva BioPharma Inc. 4340 East Kentucky Avenue Suite 206 Glendale, CO 80246 April 2, 2018 United States Securities and Exchange Commission Washington, DC 20549 Attn: Christine Westbtook, Staff Attorney Re: Intiva BioPharma Inc. Draft Registration Statement (DRS) on Form S-1 Submitted January 22, 2018 CIK No. 0001625288 Ladies and Gentlemen: This letter is in response to the staff’s comment letter

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 7, 2018 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer I

NTVA / Intiva BioPharma Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2017 Commission file number: 0-55320 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identi

NTVA / Intiva BioPharma Inc. / Bankier Alain D Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment )* INTIVA BIOPHARMA INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 46116E 103 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

Intiva BioPharma Comments on Attorney General Jeff Sessions’ Actions on January 4th that Affect State-Licensed Cannabis Businesses Intiva BioPharma indicated that Sessions’ actions in no way affect its drug development activities, nor its current or

EXHIBIT 99.1 Intiva BioPharma Comments on Attorney General Jeff Sessions? Actions on January 4th that Affect State-Licensed Cannabis Businesses Intiva BioPharma indicated that Sessions? actions in no way affect its drug development activities, nor its current or contemplated business plans Denver, Colorado: February 5, 2018 - Intiva BioPharma Inc., OTC: NTVA (?Intiva? or the ?Company?), today comm

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 5, 2018 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 000-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Emplo

INTIVA BioPharma Inc. (OTC: NTVA) Today Announced the Appointment of Lindy Snider to its Board of Directors

EXHIBIT 99.1 INTIVA BioPharma Inc. (OTC: NTVA) Today Announced the Appointment of Lindy Snider to its Board of Directors Denver, CO USA, Accesswire: Jan. 30, 2018 ? Intiva BioPharma Inc. (OTC: NTVA) (?Intiva? or ?the Company?) today announced that Lindy Snider has been appointed to the Company?s Board of Directors, effective January 26, 2018. Ms. Snider joins the Company?s Board, which also includ

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 26, 2018 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 000-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Emplo

NTVA / Intiva BioPharma Inc. DRS

As filed with the Securities and Exchange Commission on January 18, 2018. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Intiva BioPharma Inc. (Exact name of registrant as specified in its charter) Delaware 8731 26-2049376 (State or other jurisdiction of incorporation or organization) (P

NTVA / Intiva BioPharma Inc. DRSLTR

INTIVA BIOPHARMA INC. 4340 East Kentucky Avenue - Suite 206 Glendale, Colorado 80246 (303) 495-7583 [email protected] January 19, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Intiva BioPharma Inc. – Draft Registration Statement on Form S-1 Ladies and Gentlemen: On January 19, 2018, pursuant

Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 4, 2017 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Employe

NTVA / Intiva BioPharma Inc. / Intiva Usa Inc - AMENDMENT NO. 1 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 13D Under the Securities Exchange Act of 1934 INTIVA BIOPHARMA INC. (f/k/a KINDER HOLDING CORP.) (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 46116E 103 (CUSIP Number) Fay M. Matsukage 8480 E. Orchard Road, Suite 2000, Greenwood Village, CO 80111 (720) 306-1001 (Na

Kinder Holding Corp. Receives FINRA Approval for Name Change to Intiva BioPharma Inc., and the 1:6 Reverse Split of the Company’s Common Stock

Exhibit 99.1 Kinder Holding Corp. Receives FINRA Approval for Name Change to Intiva BioPharma Inc., and the 1:6 Reverse Split of the Company?s Common Stock Denver, Colorado, November 29, 2017. Kinder Holding Corp. (OTC: KDRH) today announced that approval was received on November 28, 2017 from the Financial Industry Regulatory Authority (FINRA) for: (i) the name change of the Company from Kinder H

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 29, 2017 Intiva BioPharma Inc. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Employ

KDRH / Kinder Holding Corp. DEFINITIVE INFORMATION STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement Kinder Holding Corp. (Exact Name Of

KDRH / Kinder Holding Corp. (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 Commission file number: 0-55320 Kinder Holding Corp. (Exact Name Of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identi

Kinder Holding PRELIMINARY INFORMATION STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement Kinder Holding Corp. (Exact Name Of

NTVA / Intiva BioPharma Inc. / Intiva Usa Inc Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 KINDER HOLDING CORP. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 494526 10 6 (CUSIP Number) Fay M. Matsukage 8480 E. Orchard Road, Suite 2000, Greenwood Village, CO 80111 (720) 306-1001 (Name, Address and Telephone Number of Person Autho

Amended and Restated Share Exchange Agreement dated October 13, 20171

Exhibit 99.1 Amended and Restated Share Exchange Agreement by and between Kinder Holding Corp. and Intiva BioPharma Inc. Dated as of October 13, 2017 1 This AMENDED AND RESTATED SHARE EXCHANGE AGREEMENT, dated as of October 13, 2017 (this “Agreement”) is between Kinder Holding Corp., a Delaware corporation with offices located at 2275 Huntington Drive, Suite 851, San Marino, CA 91108, on the one h

Agreement Pursuant to Rule 13d-1(k)(1)(iii) Concerning Joint Schedule 13D Filing1

Exhibit 99.2 AGREEMENT PURSUANT TO RULE 13d-1(k)(1)(iii) CONCERNING JOINT SCHEDULE 13D FILING The undersigned each agree, in connection with their beneficial ownership of common stock of Kinder Holding Corp. (i) that a Schedule 13D shall be filed jointly by them pursuant to Section 13(d) of the Securities Exchange Act of 1934 (the “Exchange Act”), together with any amendments to the Schedule 13D t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 13, 2017 Kinder Holding C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 13, 2017 Kinder Holding Corp. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer

Amended and Restated Share Exchange Agreement between the Registrant and Intiva BioPharma Inc., dated October 13, 2017

Amended and Restated Share Exchange Agreement by and between Kinder Holding Corp. and Intiva BioPharma Inc. Dated as of October 13, 2017 1 This AMENDED AND RESTATED SHARE EXCHANGE AGREEMENT, dated as of October 13, 2017 (this ?Agreement?) is between Kinder Holding Corp., a Delaware corporation with offices located at 2275 Huntington Drive, Suite 851, San Marino, CA 91108, on the one hand (the ?Com

Letter of Resignation of Ivo Heiden dated October 13, 2017 (3)

EXHIBIT 17.1 Letter of Resignation Ivo Heiden October 13, 2017 Board of Directors Kinder Holding Corp. 3773 Cherry Creek North Drive Suite 575 Denver, CO 80209 Gentlemen: Please accept this letter of resignation as accepted the resignation as the chief executive officer, chief financial officer and chairman of the Board of Directors of Kinder Holding Corp. (the ?Registrant?), effective as of Octob

KDRH / Kinder Holding Corp. ESP

Kinder Holding Corp. 2275 Huntington Drive, Suite 851 San Marino, CA 91108 September 25, 2017 United States Securities and Exchange Commission Division of Corporation Finance Attention: Danilo Castelli, Staff Attorney Washington, D.C. 205491 Re: Kinder Holding Corp. Form 8-K Staff letter dated August 29, 2017 Commission File No. 000-55320 Dear Mr. Castelli: This letter is in response to the staff'

KDRH / Kinder Holding Corp. ESP

Kinder Holding Corp. 2275 Huntington Drive, Suite 46 San Marino, CA 91108 August 16, 2017 United States Securities and Exchange Commission Washington, DC 20549 Attn: Danilo Castelli, Staff Attorney Re: Kinder Holding Corp. Form 8-K Filed June 26, 2017 File No. 000-55320 Ladies and Gentlemen: This letter is in response to the staff's letter dated July 21, 2017 (the "SEC Letter") regarding the Form

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 8, 2017 Kinder Holding Corp. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer I

Share Exchange Agreement between the Registrant and Intiva BioPharma Inc., dated August 8, 2018 (2)

? Exhibit 10.1 Share Exchange Agreement by and between Kinder Holding Corp. ?and Intiva BioPharma Inc. ? ? ? ? ? ? ? Dated as of August 8, 2017 ? This SHARE EXCHANGE AGREEMENT, dated as of August 8, 2017 (this "Agreement"), is by and between Kinder Holding Corp., a Delaware corporation with offices located at 2275 Huntington Drive, Suite 851, San Marino, CA 91108 (the "Company") and Intiva BioPhar

Kinder Holding ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED JUNE 30, 2017 (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2017 Commission file number: 0-55320 Kinder Holding Corp. (Exact Name Of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identification No.) 2

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 26, 2017 Kinder Holding Corp. (Exact Name Of Registrant As Specified In Its Charter) Commission File No.: 0-55320 Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Id

Kinder Holding FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 2017 (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 Commission file number: 0-55320 Kinder Holding Corp. (Exact Name Of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identificati

Kinder Holding FORM 10-Q FOR THE PERIOD ENDED DECEMBER 31, 2016 (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 Commission file number: 0-55320 Kinder Holding Corp. (Exact Name Of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identific

Kinder Holding FORM 10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2016 (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 Commission file number: 0-55320 Kinder Holding Corp. (Exact Name Of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identifi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 10-K _________________________________ ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended J

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2016 Commission file number: 0-55320 KINDER HOLDING CORP. (Exact Name Of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identification No.) 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 10-Q ___________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 Commission file number: 0-55320 KINDER HOLDING CORP. (Exact Name Of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identificati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 10-Q ___________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Decembe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2015 Commission file number: 0-55320 KINDER HOLDING CORP. (Exact Name Of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identific

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 10-Q ___________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Septemb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 Commission file number: 0-55320 KINDER HOLDING CORP. (Exact Name Of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identifi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 10-K _________________________________ ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended J

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2015 Commission file number: 0-55320 KINDER HOLDING CORP. (Exact Name Of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identification No.) 6

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 10-Q ___________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 Commission file number: 0-55320 KINDER HOLDING CORP. (Exact Name Of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identificati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 10-Q ___________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Decembe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-55320 KINDER HOLDING CORP

NTVA / Intiva BioPharma Inc. CORRESP - -

Kinder Holding Corp. 6230 Wilshire Blvd., Suite 46 Los Angeles, CA 90048 January 13, 2015 United States Securities and Exchange Commission Washington, DC 20549 Attn: Daniel Porco, Staff Attorney Re: Kinder Holding Corp. Form 10-12G Filed December 22, 2014 File No. 000-55320 Ladies and Gentlemen: This letter is in response to the staff's comment letter dated January 7, 2014, with respect to the abo

NTVA / Intiva BioPharma Inc. 10-12G/A - - FORM 10 AMENDMENT #3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A#3 General Form for Registration of Securities of Small Business Issuers Under Section 12(g) of the Securities Exchange Act of 1934 KINDER HOLDING CORP. (Exact Name of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identification No.) 6230 Wilshire Blvd., Suite 46

NTVA / Intiva BioPharma Inc. 10-12G/A - - FORM 10-12G/A #2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A#2 General Form for Registration of Securities of Small Business Issuers Under Section 12(g) of the Securities Exchange Act of 1934 KINDER HOLDING CORP. (Exact Name of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identification No.) 6230 Wilshire Blvd., Suite 46

NTVA / Intiva BioPharma Inc. CORRESP - -

Kinder Holding Corp. 6230 Wilshire Blvd., Suite 46 Los Angeles, CA 90048 December 19, 2014 United States Securities and Exchange Commission Washington, DC 20549 Attn: Daniel Porco, Staff Attorney Re: Kinder Holding Corp. Form 10-12G Filed December 12, 2014 File No. 000-55320 Ladies and Gentlemen: This letter is in response to the staff's comment letter dated December 18, 2014, with respect to the

NTVA / Intiva BioPharma Inc. 10-12G/A - - FORM 10-12G AMENDMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A#1 General Form for Registration of Securities of Small Business Issuers Under Section 12(g) of the Securities Exchange Act of 1934 KINDER HOLDING CORP. (Exact Name of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identification No.) 6230 Wilshire Blvd., Suite 46

NTVA / Intiva BioPharma Inc. CORRESP - -

Kinder Holding Corp. 6230 Wilshire Blvd., Suite 46 Los Angeles, CA 90048 December 12, 2014 United States Securities and Exchange Commission Washington, DC 20549 Attn: Daniel Porco, Staff Attorney Re: Kinder Holding Corp. Form 10-12G Filed November 14, 2014 File No. 000-55320 Ladies and Gentlemen: This letter is in response to the staff's comment letter dated December 4, 2014, with respect to the a

NTVA / Intiva BioPharma Inc. 10-12G - - REGISTRATION STATEMENT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 General Form for Registration of Securities of Small Business Issuers Under Section 12(g) of the Securities Exchange Act of 1934 KINDER HOLDING CORP. (Exact Name of Registrant As Specified In Its Charter) Delaware 26-2049376 (State of Incorporation) (I.R.S. Employer Identification No.) 6230 Wilshire Blvd., Suite 46, Lo

Certificate of Amendment to Certificate of Incorporation

EX-3 5 exh31ii.htm EXHIBIT 3.1 (II) STATE of DELAWARE CERTIFICATE of AMENDMENT of CERTIFICATE of INCORPORATION The corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify: FIRST: That at a meeting of the Board of Directors of Gantos, Inc. resolutions were duly adopted setting forth a proposed amendment of the Certificate of

Bylaws (1)

EX-3 6 exh32.htm EXHIBIT 3.2 TABLE OF CONTENTS Article Subject ARTICLE I OFFICES Section 1 Principal Office Section 2 Other Office ARTICLE II MEETINGS OF STOCKHOLDERS Section 1 Place of Meetings Section 2 Time and Notice of Annual Meetings Section 3 Special Meeting Section 4 Quorum Section 5 Waiver of Notice for Meetings Section 6 Record Date and Cumulative Voting Section 7 Proxies Section 8 Valid

Certificate of Incorporation

EX-3 3 exh31.htm EXHIBIT 3.1 STATE of DELAWARE CERTIFICATE of INCORPORATION A STOCK CORPORATION Article I The name of the Corporation is GANTOS, INC. Article II The Corporation's registered office in the Sate of Delaware is to be located at 16192 Coastal Highway, in the City of Lewes, DE 19958. The registered agent in charge thereof is Harvard Business Services, Inc. Article III The purpose of the

Certificate of Merger

STATE OF DELAWARE CERTIFICATE OF MERGER OF DOMESTIC CORPORATION INTO FOREIGN CORPORATION Pursuant to Title 8, Section 252 of the Delaware General Corporation Law, the undersigned corporation executed the following Certificate of Merger: FIRST: The name of each constituent corporation is GANTOS, INC.

Bankruptcy Court Order

THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF CONNECTICUT (BRIDGEPORT) In re: ) ) CHAPTER 7 ) CASE NO.